Sernivo Generic Name & Formulations
Legal Class
Rx
General Description
Betamethasone (as dipropionate) 0.05%; spray.
Pharmacological Class
Corticosteroid.
How Supplied
Spray—60mL, 120mL
Manufacturer
Generic Availability
NO
Sernivo Indications
Indications
Mild to moderate plaque psoriasis.
Sernivo Dosage and Administration
Adult
≥18yrs: apply to affected areas twice daily for up to max 4 weeks; discontinue when control is achieved. Do not occlude.
Children
<18yrs: not recommended.
Sernivo Contraindications
Not Applicable
Sernivo Boxed Warnings
Not Applicable
Sernivo Warnings/Precautions
Warnings/Precautions
Not for oral, ophthalmic, or intravaginal use. Avoid use on face, scalp, axilla, groin, or other intertriginous areas. Do not use on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, reduce dose, or substitute with less potent corticosteroid if occurs. Potential risk of posterior subcapsular cataracts and glaucoma. Avoid abrupt cessation in chronic use. Reevaluate periodically. Pregnancy. Nursing mothers: avoid infant exposure.
Sernivo Pharmacokinetics
See Literature
Sernivo Interactions
Not Applicable
Sernivo Adverse Reactions
Adverse Reactions
Pruritus, burning, stinging, pain, atrophy; allergic contact dermatitis (discontinue if irritation occurs), HPA axis suppression (esp. in children), visual disturbances; rare: Cushing's syndrome, hyperglycemia, glucosuria.
Sernivo Clinical Trials
See Literature
Sernivo Note
Not Applicable
Sernivo Patient Counseling
See Literature
Images
